On July 6, True Health Medical-B fell 5.99% in regular trading, trading at 385.2 HKD/share, with turnover of HKD 2.4179 million. The stock continues to face selling pressure following its extraordinary post-IPO surge.

The company listed on the Hong Kong Stock Exchange on June 30 at an offer price of 126.2 HKD, closing its debut session at 400 HKD — a gain exceeding 217%. The short-term cumulative gain surpassed 200%, and on July 3 the stock already experienced a notable intraday pullback exceeding 7%. Profit-taking continues to weigh on the shares amid elevated valuations.

Fundamentally, the company remains in early-stage commercialization. Its 2025 revenue was approximately RMB 12.18 million, with a net loss of approximately RMB 90.13 million and cumulative losses reaching RMB 1.537 billion. The extreme valuation premium relative to its current financials is intensifying selling pressure from short-term holders locking in gains.

The company is principally engaged in the research, development, and commercialization of percutaneous puncture surgical robots and ablation surgical robots in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)